Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 10Temozolomide 8X-Rays 7Specimen Handling 7Irinotecan 7Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Filgrastim 6Carboplatin 5Biopsy 5fludarabine 4Nuclear Medicine Department, Hospital 4olaparib 3fludarabine phosphate 3etoposide phosphate 3dinutuximab 3Zoledronic Acid 3Oxaliplatin 3Nivolumab 3Ifosfamide 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Etoposide 3Docetaxel 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2lorukafusp alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × GRN163L peptide × CNS × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡